Lates News

CASI Pharmaceuticals (CASI.US): The Q1 financial report for 2025 achieved revenue of $6.24 million, up from the previous value of $3.409 million, and higher than the expected value of $6.1 million. Earnings per share were -$0.69, an improvement from the previous value of -$0.71, but lower than the expected value of -$0.60.